Tagged with Urology

Switzerland Amid a crowded landscape of incremental innovation, Synendos Therapeutics stands out for its bold approach to neuropsychiatric drug development. Co-Founder and CEO Andrea Chicca shares how the company emerged from a translational research programme in Switzerland to pioneer a first-in-class therapeutic strategy targeting the endocannabinoid system, a master regulator of…

Hong Kong Professor at the Chinese University of Hong Kong since 1993 and pioneer in studying the causes of stroke in China, Lawrence Wong comments on neurology advancements over the past 30 years; the increasing number of Alzheimer’s cases amongst Asian populations, and the need to go from a symptomatic approach to…

Spain UCB’s general manager for Iberia, Pau Ricós, comments on the Belgian company’s upcoming launches, its focus on immunology and neurology, and the importance of R&D – UCB spent around 28 percent of its revenues on R&D in 2021. In addition, Ricós analyses Spain’s slow access to innovation and the pros…

Italy Merck Italia’s Managing Director & President, Jan Kirsten explains the importance of the Italian affiliate within the global organisation, Merck’s aim to strengthen its position in oncology and the challenges of fertility in a country with one of the lowest birthrates in the world. [In Italy] we have the full…

Italy Medac Pharma Italy’s Giovanni Sala describes the Italian affiliate’s unique portfolio of haematology, onco-urology, and neurosurgery products, as well as generics, and outlines the challenges of the Italian market.   … in Italy we have developed a dual strategy: on one side in-licence local generic products; while on the other…

Japan Founded by Toyoji Naito in December 1941, in just under 80 years, Eisai has become a leading global biopharma player, with pharmaceutical revenues of USD 5.4 billion in 2019.   The company’s central philosophy of human health care (hhc) was introduced in 1992 by current director, representative corporate officer and…

Belgium Chantal Depondt, president of the Belgian Neurological Society (BNS), introduces the mission of the professional association and offers her insights into the healthcare and research dynamics surrounding neurological diseases. Depondt also delivers a clear message about the importance of continued public and private investments in basic research to foster new…

France Newly-appointed general manager of UCB France, Catherine Rives, discusses what drew her back to the company after time away, market access issues in France and the future of personalized medicine.   My mission is very clearly to raise the profile of the French affiliate within the UCB Group and simultaneously…

Turkey Hande Demirdere, general manager of Pierre Fabre Pharma in Turkey, sheds light on the affiliate’s impressive 93 percent growth in 2017 while highlighting where to target development opportunities in the dynamic Turkish market. In this interview, the experienced General Manager discusses the advantages of diversifying strategies, Pierre Fabre’s comparative advantage…

UK Terry O’Regan, VP and managing director at Biogen UK and Ireland, discusses the company’s longstanding commitment to the UK, market access issues, and why Biogen is staying the course with developing Alzheimer’s products at a time when many MNCs are winding down their neurology programs. How would you describe Biogen’s…

Canada Lee Ferreira, newly-appointed general manager of Ferring Pharmaceuticals Canada, shares her excitement about the company’s transformative changes. She stresses the importance of conducting research in Canada in all areas of the organization’s portfolio, from reproductive medicine and women’s health to gastroenterology and urology.  Lee, what are your main priorities coming…

UK Recipient of the 2018 Brain Prize for research for groundbreaking research on the generic and molecular basis of Alzheimer’s Disease, the UCL’s Professor John Hardy discusses recent progress in dementia research, the strengths and weaknesses of the UK’s medical research environment, and the potential effects of Brexit.   In all…